Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gestational Trophoblastic Neoplasia
Conditions
Gestational Trophoblastic Neoplasia
Trial Timeline
Jan 27, 2022 → Jan 1, 2027
NCT ID
NCT05139095About Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B
Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Gestational Trophoblastic Neoplasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05139095. Target conditions include Gestational Trophoblastic Neoplasia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05139095 | Phase 2 | Recruiting |
Competing Products
18 competing products in Gestational Trophoblastic Neoplasia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| somatropin | Eli Lilly | Phase 3 | 77 |
| Insulin LISPRO + Insulin, Long-Acting and Insulin | Eli Lilly | Approved | 85 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 52 |
| recombinant somatropin | Merck | Pre-clinical | 23 |
| Recombinant human growth hormone (r-hGH) | Merck | Phase 3 | 77 |
| Avelumab Injection + Methotrexate 1 GM Injection | Merck | Phase 1/2 | 41 |
| Saizen® + Saizen® | Merck | Phase 3 | 77 |
| Metformin + placebo | Novo Nordisk | Approved | 84 |
| Metformin XR plus placebo + Metformin XR plus liraglutide | Novo Nordisk | Phase 3 | 76 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 51 |
| Liraglutide + Placebo | Novo Nordisk | Approved | 84 |
| Genotropin (PN-180,307) Somatropin + Control-no treatment | Pfizer | Phase 3 | 76 |
| growth hormone | Pfizer | Pre-clinical | 22 |
| Somatropin | Pfizer | Pre-clinical | 22 |
| Somatropin | Pfizer | Pre-clinical | 22 |
| Genotropin (somatropin) | Pfizer | Approved | 84 |
| Omnitrope | Sandoz Group | Approved | 82 |
| Inhaled Technosphere Insulin | MannKind Corp | Phase 2/3 | 60 |